https://www.indianpharmapost.com/jb-pharma-q2-fy24-pat-up-36-to-rs-151-cr-148962023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/iol-chemicals-and-pharmaceuticals-q2-pat-jumps-141-to-rs-378-cr-148972023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/kesin-pharma-announces-fda-approval-and-availability-of-likmez-oral-suspension-148982023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/teva-royalty-pharma-collaborate-to-further-accelerate-olanzapine-lai-program-148992023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/wockhardt-q2-fy24-consolidated-loss-lowers-at-rs-77-cr-149002023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/natco-pharma-posts-consolidated-q2f-y24-pat-of-rs-369-cr-149012023-11-15T00:00:00+05:30always0.9https://www.indianpharmapost.com/solara-active-pharma-sciences-posts-consolidated-q2-fy2024-loss-at-rs-1716-cr-149022023-11-15T00:00:00+05:30always0.9